Docket Number:13A-1000908
Inventor:Yu-Chan Chao, Yueh-Lung, Wu, Carol PeiYin Wu
IP Status:TW I487710
Abstract:
The Epstein-Barr virus (EBV) is a human herpes virus that infects 90% of individuals. Primary EBV infection targets resting B lymphocytes, inducing their continuous proliferation. In the B lymphoblastoid cell lines, only limited numbers of viral genes are usually expressed and there is no production of virus particles, this is called latent infection. In the latent state, EBV maintains its 165-kbp genome as complete, multiple copies of plasmids. Latent phase viral replication appears to faithfully mimic cellular replicons; the EBV genomes or small EBNA1-oriP plasmids, which contains viral replication origin, are synthesized only once in each S-phase by the host cell replication machinery, following the rules of chromosome replication. EBV-infected cell lines usually contain a small subpopulation of cells that have switched spontaneously from a latent stage of infection into the lytic cycle. In these studies, cellular microRNAs, which were predicted to target oriP sequence based on computer analysis, were synthesized and their ability to influence oriP-dependent replication was assessed in human embryonic kidney (HEK293) cells. Transient transfection results showed that oriP-dependent replication was suppressed by the addition of some of the predicated microRNAs, and these results proved that microRNAs could play a role in regulating EBV genome replication during latent infection. Thus, our results showed that it is possible to control viral replication by increasing the amounts of cellular miRNA, or synthesized siRNA based on the sequence of the replication origin.
Fields of Application:
EBV is a carcinogenic factor and associated with nasopharyngeal carcinomas, gastric carcinoma and several lymphoid malignancies. EBNA1 is an EBV-encoded protein and trigger EBV replication in EBV-infected cells. Here, we found that EBV replication can be inhibited by microRNA targeting to OriP, which is the binding site of EBNA1. By competing of microRNA and EBNA1 at the site, EBV replication can be effectively controlled by microRNA during EBV latent infection.
Advantages when compared to the existing technologies:
In the past decade, identification of small molecule for drug discovering of EBV is cost-inefficient and time-consuming process which needs high through-put screening. By computational analysis of specific interaction between microRNA and OriP sequence, which is much effectively and economically, the candidate microRNAs can be determined. Furthermore, we had proved the candidate microRNA can directly bind to OriP sequence and compete with EBNA1 which can regulate EBV replication in latent infection cells. This is the first discovery that microRNA can interact and regulate DNA replication.
Contact Person:Sue-Ming Chang / 886-2-2787-2600 / name4517@gate.sinica.edu.tw
